Clinical details regarding sarcoidosis chronicity, organ involvement and treatment for each of the 14 subjects in the sarcoidosis group
| Subject | Years since diagnosis | Organ involvement | Treatment | Prednisone equivalent mg | Absolute lymphocyte count (109 cells·L−1) |
| 1# | 26 | Pulmonary | Steroids, anti-metabolite, anti-TNF, IVIG | 10 | 0.9 |
| 2 | 2 | Lymph node | Steroids, HCQ | 7.5 | 1.2 |
| 3 | 13 | Pulmonary, ocular | Steroids, anti-metabolite | 2.5 | 3.0 |
| 4 | 8 | Pulmonary, neurological | Steroids | 5 | NA |
| 5# | 12 | Pulmonary, cardiac | None | 0 | 1.2 |
| 6 | 24 | Pulmonary | None | 0 | 2.0 |
| 7 | 41 | Pulmonary | None | 0 | 1.7 |
| 8# | 11 | Pulmonary | Steroids, anti-TNF, IVIG | 15 | 3.1 |
| 9 | 10 | Pulmonary, neurological, hepatic | Steroids, anti-metabolite, anti-TNF | 10 | 1.6 |
| 10 | 6 | Pulmonary | HCQ | 0 | 1.7 |
| 11 | 8 | Pulmonary | None | 0 | 2.9 |
| 12 | 7 | Pulmonary, ocular | Anti-metabolite, anti-TNF | 0 | 1.9 |
| 13 | 30 | Pulmonary | None | 0 | NA |
| 14 | 7 | Pulmonary | None | 0 | 2.0 |
TNF: tumour necrosis factor; IVIG: intravenous immunoglobulin; HCQ: hydroxychloroquine. #: 6-month time point not available.